Summit Therapeutics SMMT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $132.62M+159% | $147.29M+187% | $131.1M+248% | $208.02M+575% | $51.27M+66.1% | ||
| $62.59M+302% | $77.63M+445% | $103.12M+399% | $360.42M+2,509% | $15.59M+35.3% | ||
| $195.21M+192% | $224.93M+243% | $234.21M+301% | $568.44M+853% | $66.85M+57.7% | ||
| $5.79M+47.0% | $5.75M+30.2% | $2.42M-47.2% | $2.73M+16.9% | $3.94M+93.3% | ||
| -$189.42M-201% | -$219.17M-258% | -$231.79M-312% | -$565.71M-837% | -$62.91M-44.7% | ||
| -$0.24-167% | -$0.28-211% | -$0.31-287% | -$0.76-744% | -$0.09-50.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Summit Therapeutics profitable?
- Summit Therapeutics is not currently profitable: it reported a net loss of $1.2B over the trailing twelve months, a -271685.0% net margin.
- What is Summit Therapeutics's earnings per share?
- Summit Therapeutics's diluted EPS over the trailing twelve months is $-1.59.
- Where does Summit Therapeutics's income statement data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.